News Article | February 28, 2017
Research and Markets has announced the addition of the "Infusion Pumps - Global Strategic Business Report" report to their offering. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. This report analyzes the worldwide markets for Infusion Pumps in US$ by the following Product Segments: The report profiles 52 companies including many key and niche players such as: - Infusion Pumps: An Alternate Drug Delivery Option - Current and Future Analysis - Developed Economies Dominate Infusion Pumps Market - Asia-Pacific: The Fastest Growing Market for Infusion Pumps - Analysis by Product Segments - Ambulatory Infusion Pumps - Enteral Feeding Pumps - Insulin Infusion Pumps - Large Volume Infusion Pumps - PCA Infusion Pumps - Syringe Infusion Pumps - Infusion Errors & Technology Defenses Developed Over the Years - Rise in Incidence of Chronic Diseases Fuels Infusion Pumps Demand - The Diabetes Epidemic - Untapped Potential for Insulin Pumps - Global Diabetes Expenditure: Opportunity Indicator for Insulin Pumps Market - Cancer Pain Offers Potential Opportunities for Pain Management Pumps - Infusion Pumps - A Highly Consolidated Market - Insulin Pumps Market - Competition Intensifies - Comparison of Select Durable Insulin Pumps by Manufacturer - Medtronic Banks on New Solutions and Distribution Expansion to Retain Dominance - J&J's OneTouch Via - A Discrete Solution for On-Demand Insulin - Ypsomed Eyes Brighter Prospects with YpsoPump - Medtrum - A New Entrant with a Strong Product; Threatening to Take the Market by Storm - Competitive Landscape in the Insulin Patch Pump Market - OmniPod Benefits from Lack of Close Competition in its League - Insulet Focuses on Advances in Technology and Services to Gain Market Share - Cellnovo's Patch Pump Combines Functionality and Cost- Effectiveness - V-Go - An Affordable Patch Pump for Type II Diabetics - Expiry of Warranty Provides New Opportunities to Insulin Pump Makers - Customer Satisfaction: Crucial to Stay Competitive - Enteral Feeding Devices: An Intensely Competitive Market - Multinationals Target Emerging Markets - The New Hotspots for Growth - Infusion Errors: A Key Driving Force for Newer Technologies - Manufacturers Focus on Interoperability with EMR Systems - Security of Wireless Medical Device - A Vital Factor - Shift from Hospital Environments to Alternative-Sites/ Home Settings Drives the market for Home Infusion Pumps - Product Complexity Thwarts ROI on Devices - Smart Pump Technology: A Major Growth Driver - Smart Pumps with Innovative Features - Improving Functionality for Enhanced Patient Compliance - Maintaining Smartness Quotient of Smart Infusion Pumps - Product Bundling: A Double Whammy Success - Analgesia Infusion Pumps Continue to Register Favorable Growth - Disposable Ambulatory Infusion Pumps Market Exhibits Notable Stride Forward - Enteral Feeding Pumps Market Overview - Replacements Offer Potential Growth Opportunities - Preference for Enteral Nutrition over Parenteral Nutrition Bodes Well - Advantages and Disadvantages of Enteral Nutrition over Parenteral Nutrition - Enteral Nutrition Therapy in Treating Adult Malnutrition Offers Growth Opportunities - Home Enteral Therapy to Boost Demand for Enteral Feeding Devices - Insulin Pumps - Designed for Optimum Disease Management - The Rise of Smart Pumps - Manufacturers Eye Type II Diabetes Market - Implantable Insulin Pumps - The Next Generation of Insulin Pumps - Patch Pumps Gain Manufacturer Attention - Insulin Pump Training - An Important Driver - Complicated Insulin Pump Software Makes Pump Use Difficult for the Aged - Competition from Other Insulin Delivery Technologies Continues - Maturity Hits Volumetric Infusion Pumps Market - Equipment Recalls Thwarts Growth Prospects - Stringent Safety Regulations Impede Time-to-Market - Look into Select Technology Advancements - Ivenix Develops Next-Generation Infusion Management Platform - Innovfusion Develops Advanced Infusion Pumps to Provide Relief from Labor Pain - Summit Medical's Low-Cost Portable Infusion Pumps Improve Patient Care - Product Malfunctioning Erodes Penetration of Implantable Infusion Pumps Rise in Healthcare Spending in Developing Nations Bode Well for the Market Aging Population: A Strong Growth Driver Global Aging Population Statistics Opportunity Indicators Rise in Incidence of Cancer and Central Nervous System Diseases Foster Growth World Cancer Statistics: Incidence and Mortality Data Diabetes Incidence and Prevalence Global Diabetic Statistics Opportunity Indicators Alarming Rise in Obesity A Business Case for Diabetes Care Rise in HIV Prevalence Provides Ample Growth Opportunities Global HIV Statistics Opportunity Indicators for Enteral Feeding Devices - FDA Announces Initiative to Address Safety Concerns Related to Infusion Pumps - FDA Announces a New Mandate for Manufacturing Companies - Regulations Promote Adoption of Premium-Priced Safety Devices - ISO 80369 Standards for Small-Bore Connector - ENFit - The New ISO Standard Enteral Feeding Connecting System - Infusion Pumps: A Definition - Types of Infusion Pumps - Ambulatory Infusion Pumps - Non-Electronic Ambulatory Infusion Pumps - Advantages & Disadvantages of Non-Electronic Pumps - Electronic Ambulatory Infusion Pumps - Nerve Block Infusion Pumps - Enteral Feeding Pumps - Insulin Infusion Pumps - Large Volume Infusion Pumps - Pump Architecture of Volumetric Pumps - Classification by End-Use Application - Volumetric Pumps used in Acute Care Settings - Volumetric Pumps used in Alternate Care Settings - Patient Controlled Analgesic (PCA) Pumps - Syringe Infusion Pumps - Low-End and High-End Syringe Pumps - Implantable Infusion Pumps - Programmable Implantable Infusion Pumps - Constant Flow Implantable Infusion Pumps - Approved Applications of Implantable Infusion Pumps - Common Safety Features Available In Most Infusion Pumps - Key Problems Reported with Infusion Pumps - User Interface Issues - Software Issues - Alarm Errors - Damaged Components - Battery Failures - Fire, Shocks, Sparks or Charring - Intelligraphics Enters into Collaboration with Ivenixto Develop Intelligent Infusion Pump Platform - Smiths Medical Introduces New Software Version for use with Medfusion® 4000 wireless syringe pumps - Caesarea Medical Announces Launch of its latest Dual Channel Infusion Pump - Medtronic Launches MiniMed® 630G System - Hospira Introduces LifeCare PCA 7.0 infusion pump with EMR Connectivity - Smiths Medical Launches New CADD®-Solis Pump - Animas Bags FDA Approval for Animas® Vibe® Insulin Pump and Continuous Glucose Monitoring System - Medtronic Rolls Out MiniMed 640G Insulin Pump - B. Braun Medical Secures FDA Approval for Infusomat® Space Pump - Zyno Medical Gains CE Mark Approval for Z-800 Infusion Pump System - Hospira Receives FDA Clearance for Plum 360 Infusion System - BioLeonhardt Develops Stem Cell Pump - Animas Rolls Out Animas® Vibe Insulin Pump with Latest Dexcom CGM Technology - Baxter Gets FDA Clearance for SIGMA Spectrum Infusion Pump with Master Drug Library - Animas Bags CE Mark Approval for Animas® Vibe Insulin Pump and Dexcom G4 PLATINUM CGM System - Animas Secures FDA Approval for Animas® Vibe Insulin Pump and Continuous Glucose Monitoring System Omnicell and Hospira Collaborate for System Interoperability BD Enters into Collaboration with JDRF to Develop Extended Wear Innovations for Insulin Infusion Delivery Teleflex Signs Group Purchasing Agreement with Premier Inc. for Implantable Infusion Ports ICU Medical to Acquire Pfizer's Infusion Therapy Business Zyno Medical Receives FDA 510(k) Clearance for Nimbus II Ambulatory Infusion System InfuSystem to Acquire Infusion Pump Assets from InfusAID, LLC Medtronic to Manufacture and Deploy Advanced Diabetes Therapies in Chengdu, China Pfizer Considers Sale of the Infusion Pump Business Pfizer Acquires Hospira InfuSystem Completes Acquisition of Ciscura Becton Dickinson Takes Over CareFusion Hospira Inks Agreement with Cerner for Developing Infusion Pump Information Platform Animas Partners with Tidepool Medtronic Partners with BD to Develop New Insulin Pump with BD FlowSmart Technology Fresenius Kabi Inks Agreement with Amerinet Hospira Faces Class I Recall of GemStar Infusion System - Animas Corporation (USA) - Baxter International Inc. (USA) - B. Braun Melsungen AG (Germany) - Becton, Dickinson and Company (USA) - F. Hoffmann-La Roche Ltd. (Switzerland) - Fresenius SE & Co. KGaA (Germany) - Halyard Health, Inc. (USA) - Hospira, Inc. (USA) - ICU Medical, Inc. (USA) - Insulet Corporation (USA) - Medtronic, PLC (Ireland) - Moog, Inc. (USA) - Smiths Medical (USA) - Sooil Development Co. Ltd. (Korea) - Tandem Diabetes Care, Inc. (USA) - Teleflex Incorporated (USA) - Terumo Corporation (Japan) - The United States - Japan - Europe - France - Germany - The United Kingdom - Rest of Europe - Asia-Pacific (Excluding Japan) - Middle East - Latin America For more information about this report visit http://www.researchandmarkets.com/research/cq3cv2/infusion_pumps
News Article | February 28, 2017
DUBLIN, 28-Feb-2017 — /EuropaWire/ — Medtronic plc (NYSE:MDT) today announced an economic analysis of five-year data showing that patients with mild heart failure who get cardiac resynchronization therapy (CRT) devices early in their treatment live longer and that implanting these devices is cost-effective, compared to optimal medical therapy. Results from the REVERSE (REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction) trial were published in the Journal of the American College of Cardiology: Heart Failure. CRT is an established treatment for indicated patients with heart failure that has been demonstrated to improve survival and quality of life, and reduce hospitalizations. However, despite significant clinical evidence and guideline recommendations in support of CRT, studies have shown the therapy to be underutilized in eligible patients1. REVERSE is the largest study to assess the long-term clinical impact and survival benefit of devices combining CRT with a defibrillator compared with CRT pacemakers. It is also the first study to show the cost-effectiveness of CRT when implanted earlier in the disease state. “These new data expand upon the current evidence and guidelines for the treatment of heart failure, by showing that CRT in patients with mildly symptomatic heart failure is beneficial, both from a clinical perspective, as well as from a financial perspective,” said Michael R. Gold, M.D., Ph.D., chief of cardiology, Michael E Assey Professor of Medicine at the Medical University of South Carolina. “REVERSE confirms that implanting CRT earlier slows the progression of heart failure, reduces heart failure-related hospitalizations and deaths, and prolongs life, all while being very cost-effective.” REVERSE was a prospective, randomized, double-blind study of 610 patients with mild heart failure (those designated New York Heart Association Class I/II) from North America and Europe. All patients were implanted with a CRT-pacemaker (CRT-P) or -defibrillator (CRT-D) and randomly assigned (2:1) to either CRT-ON or CRT-OFF. Previously published REVERSE findings showed a trend that CRT-ON increased survival by nearly 23 percent (52.5 percent vs. 29.7 percent, p=0.21), leading to an expected survival rate of 9.76 years for CRT-ON versus 7.5 years for CRT-OFF2. Based on these findings, the new analysis shows – for the first time under the Medicare setting – that CRT is a cost-effective option for patients with mild heart failure: CRT-ON yields an incremental cost effectiveness ratio (ICER) of $8,840 per Quality-Adjusted Life Year (QALY) gained over a patient’s lifetime, compared to CRT-OFF. (ICER is a statistic that summarizes the cost-effectiveness of a healthcare intervention, and QALY is a measure of the quantity and quality of life.) Additionally, REVERSE has shown that CRT-D provides a significant improvement in survival – 2.77 additional years of life – compared to CRT-P devices2. This benefit results in a first-of-its-kind finding that CRT-D is a cost-effective alternative to CRT-P, yielding an ICER of $43,678/QALY gained over the patient’s lifetime, lower than the benchmark for therapy cost effectiveness of other serious chronic conditions that cost at least $50,000 per QALY gained. Thus, while CRT-D costs more than CRT-P, the added 2.77 years of life justify the additional cost over a patient’s lifetime2. Finally, these analyses show CRT delays disease progression, which means that initially implanting a CRT-D is essentially cost-neutral compared to implanting an ICD and implanting a CRT-D later, when the disease worsens. With early CRT-D implantation slowing disease progress and increasing survival, and without any discounting of future benefits and cost applied, early CRT-D led to 1.24 years of additional survival, resulting in an ICER of $1,829 per year of life gained. “While CRT has long been established as a therapy that significantly improves outcomes for patients with heart failure, it is consistently underutilized,” said David Steinhaus, M.D., vice president and general manager of the Heart Failure business, and medical director for the Cardiac Rhythm and Heart Failure division of Medtronic. “Not only does REVERSE demonstrate the clinical benefit of CRT, it also quantifies the economic value of CRT, providing hospital systems with valuable information to help make informed decisions about CRT as a treatment option and the optimal timing of CRT for patients with heart failure. Ultimately, the goal is to increase value by improving patient outcomes and optimizing costs.” In collaboration with leading clinicians, researchers and scientists worldwide, Medtronic offers the broadest range of innovative medical technology for the interventional and surgical treatment of cardiovascular disease and cardiac arrhythmias. The company strives to offer products and services of the highest quality that deliver clinical and economic value to healthcare consumers and providers around the world. About Medtronic Medtronic plc (www.medtronic.com), headquartered in Dublin, Ireland, is among the world’s largest medical technology, services and solutions companies – alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 88,000 people worldwide, serving physicians, hospitals and patients in approximately 160 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together. Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic’s periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results. 1 Fonarow GC, Yancy CW, Albert NM, et al. Improving the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting: (IMPROVE HF). Circulation. August 10, 2010;122(6):585-96. 2 Gold MR, Padhair A, Mealing S, et al. Long-Term Extrapolation of Clinical Benefits Among Patients With Mild Heart Failure Receiving Cardiac Resynchronization Therapy: Analysis of the 5-Year Follow-Up from the REVERSE Study. JACC Heart Fail. 2015 Sep;3(9):691-700.
News Article | February 23, 2017
Heart failure patients registered in the Swedish Heart Failure Registry receive better medication and have a 35 percent lower risk of death than unregistered patients, according to a new study from Karolinska Institutet in Sweden. The findings are presented in the European Journal of Heart Failure. Health quality registries are used for many purposes including to report quality of care and to identify areas for quality improvement. Sweden has been a pioneer in the establishment of quality registries for a broad range of diseases. The Swedish Heart Failure Registry (SwedeHF; RiksSvikt) registers clinical and treatment data for patients with heart failure from most hospitals in Sweden. RiksSvikt is voluntary, so some but not other patients get registered, and this is determined largely by the availability of staff and resources at local hospitals. In the current study, a Swedish team comprising researchers at Karolinska Institutet, Linköping University, and Uppsala Clinical Research Center analyzed data from 231,437 patients who were diagnosed with heart failure in Sweden 2006-2013. A comparison between those who were registered in RiksSvikt and those who were not showed that the registered patients had a remarkable 35 percent lower risk of death. The investment in quality registries in Sweden has provided helpful quality reporting and contributed to improved quality of care, but the concrete health benefits for patients have been less clear. "Now we also see that in heart failure, quality reporting translates directly into better survival," says Associate Professor Lars H. Lund at Karolinska Institutet's Department of Medicine who led the study. "It is imperative that the investment in registries from the government, hospitals and clinicians continues to expand, as this will lead to better patient survival". Further analyses showed that patients who were registered in RiksSvikt were more likely to receive heart failure medications than unregistered patients, and that this to a large extent explained the difference in survival. "There are several common treatments for heart failure which are known to cost-effectively reduce the risk of hospitalization and death, but these are underutilized," says Associate Professor Lars H. Lund. Heart failure is a common condition in which the heart is unable to pump sufficient quantities of blood around the body. It is the most common cause of hospitalization in Sweden and is associated with a high risk of death. The study was financed by The Swedish Research Council, The Swedish Heart-Lung Foundation, The Stockholm County Council and AstraZeneca. There are no conflicts of interest declared related to the study. Outside the work submitted, some of the researchers have received research grants, speaker's fees and/or consulting fees from AstraZeneca, Novartis, Bayer, Vifor Pharma, Relypsa, Boston Scientific, St Jude, Medtronic, HeartWare and Aspen Pharma. One of the researchers is employed as epidemiologist by AstraZeneca. Publication: "Association between enrolment in a heart failure quality registry and subsequent mortality - a nationwide cohort study". Lund LH, Carrero J, Farahmand B, Henriksson KM, Jonsson Å, Jernberg T, Dahlström U. European Journal of Heart Failure, online 23 Feb 2017. doi: 10.1002/ejhf.762.
News Article | March 1, 2017
Notice is hereby given of the annual general meeting of H. Lundbeck A/S to be held on: The general meeting will be held at the offices of the Company at: In accordance with Article 8.1 of the Articles of Association, the agenda of the meeting is as follows: 7.1 Proposal from the Board of Directors to authorise the Board of Directors to allow the Company to acquire own shares. 7.2 Proposal from the Board of Directors to authorise the Chairman of the meeting to file for registration of the resolutions passed at the general meeting with the Danish Business Authority. The Board of Directors recommends that the report be adopted. The Board of Directors proposes that the annual report be approved. The Board of Directors proposes to distribute a dividend of 40% of the net profit for the accounting year 2016, corresponding to DKK 2.45 per share, or a total dividend of DKK 484 million. The Board of Directors of H. Lundbeck A/S should consist of persons who together possess the financial, pharmaceutical and international qualifications required for safeguarding the Company's and, thus, the shareholders' interests in the best manner possible having regard to the Company's other stakeholders. The Board of Directors' most important duties are to formulate Lundbeck's overall strategy, set specific objectives for the Company's Executive Management and ensure that the members of the Executive Management have the right qualifications. For a more detailed description of the qualifications required for members of the Board of Directors, please see the Company's website: www.lundbeck.comà About Us à Corporate Governance. Members of the Board of Directors elected by the general meeting are elected or re-elected every year, and therefore the term of office of the current members expires in connection with this annual general meeting. The Board of Directors proposes that the following members elected by the general meeting should be re-elected: Lars Rasmussen, Lene Skole, Lars Holmqvist and Jesper Ovesen. In addition, the Board of Directors proposes that Jeremy M. Levin is elected. Terrie Curran does not wish to stand for re-election. The Board of Directors expects to elect Lars Rasmussen as Chairman and elect Lene Skole as Deputy Chairman. The Board of Directors assesses that the candidates together possess the professional and international experience required for maintaining the Company's position as a leading global pharmaceutical company focusing on research and development in the field of brain disorders. The Board of Directors also considers the size of the Board appropriate taking into account the Company's needs and the aim of ensuring constructive debate and effective decision-making. Regard has been given to diversity in the selection of board candidates. The Recommendations on Corporate Governance recommend that at least half of a company's board members elected by the general meeting should be independent of the company. Lars Rasmussen, Jesper Ovesen and Jeremy M. Levin meet the criteria for independence. Lene Skole and Lars Holmqvist are considered to be non-independent board members due to their responsibilities in the Lundbeck Foundation. If the proposed candidates are elected to the Board of Directors, the Board will meet the recommendation for independence as defined by the Recommendations on Corporate Governance. The proposed board candidates have the following backgrounds: Lars Rasmussen, BSc Engineering and MBA, was born on 31 March 1959 and is a Danish citizen. He was nominated for election to Lundbeck's Board of Directors at the 2013 annual general meeting. He chairs Lundbeck’s Remuneration and Scientific Committees, and is member of Lundbeck's Audit Committee. Lars Rasmussen has considerable management experience in global med-tech. Lars Rasmussen was appointed as CEO of Coloplast A/S in 2008 and has been member of the company's executive management since 2001. In this period, he has been responsible for various functions in the group, including global sales, innovation and production. He has performed these duties from both Denmark and the USA. Lars Rasmussen's special qualifications for serving on Lundbeck's Board of Directors include his top management experience and knowledge of efficiency improvements and internationalisation. Lars Rasmussen is member of the Board of Directors of William Demant Holding A/S. Lene Skole, BCom Finance, was born on 28 April 1959 and is a Danish citizen. She was nominated for election to Lundbeck’s Board of Directors at the 2015 annual general meeting. She is member of Lundbeck's Remuneration and Scientific Committees. Lene Skole is CEO at the Lundbeck Foundation. Prior to joining the Lundbeck Foundation in 2014, Lene Skole was CFO at Coloplast A/S where she was a member of the company’s executive management since joining in 2005. Lene Skole’s responsibilities included finance, IT, HR, communication, strategy and M&A. Before 2005, Lene Skole held various positions in the AP Moller-Maersk group most recently as CFO of Maersk Company Ltd., London from 2000-2005. Lene Skole’s special qualifications for serving on Lundbeck’s Board of Directors include extensive knowledge and expertise within financing, strategy, business development and M&A as well as management experience from international companies including med-tech. Lene Skole is vice chairman of the Board of Directors of DONG Energy A/S, Falck A/S, ALK-Abelló A/S, and member of the Board of Directors of Tryg A/S and Tryg Forsikring A/S. Lars Holmqvist, MSc in business administration, was born on 4 September 1959 and is a Swedish citizen. He was nominated for election to Lundbeck’s Board of Directors at the 2015 annual general meeting. He is member of Lundbeck’s Audit Committee. Lars Holmqvist is senior advisor within healthcare at Bain Capital. He previously served as vice president responsible for sales and marketing at Pharmacia. In addition he has held management positions in several pharma and med-tech companies including Boston Scientific Corporation, Medtronic, Applied Biosystems Group, DAKO and Agilent Technologies. Lars Holmqvist’s special qualifications for serving on Lundbeck`s Board of Directors include his international management experience, his expertise in finance, and his sales and marketing experience from the global pharmaceutical, med-tech and life-science industry. Lars Holmqvist is member of the Board of Directors of the Lundbeck Foundation, ALK-Abelló A/S, Tecan AG and BPL Ltd. Jesper Ovesen, MSc in finance and state authorized public accountant, was born on 20 March 1957 and is a Danish citizen. He was nominated for election to Lundbeck’s Board of Directors at the 2015 annual general meeting and chairs Lundbeck’s Audit Committee. Jesper Ovesen most recently held the position of executive chairman of the Board of Directors of Nokia Siemens Networks BV. Prior to this, he served as CFO in TDC A/S, Lego A/S and Danske Bank A/S, and finance director at Novo Nordisk A/S. Jesper Ovesen’s special qualifications for serving on Lundbeck’s Board of Directors include his international management experience and his expertise in finance, accounting and international capital markets. Jesper Ovesen is vice chairman of the Board of Directors of Scandinaviska Enskilda Banken AB and member of the Board of Directors of Sunrise Communications Group AG and ConvaTec Group PLC. Jeremy M. Levin, BA Zoology, MA and DPhil in Molecular Biology and MB BChir Medicine and Surgery, was born on 9 September 1953 and is a British and US citizen. He is nominated for election to Lundbeck’s Board of Directors at the 2017 annual general meeting. Jeremy M. Levin has more than 25 years of experience in the global pharmaceuticals industry, leading companies and people to develop and commercialize medicines that address compelling medical needs worldwide. Since 2014, he has been CEO and chairman of Ovid Therapeutics, a New York-based neurology company focused on rare and orphan diseases of the brain. Previously, Jeremy M. Levin served as President & CEO of Teva Pharmaceuticals and before becoming CEO of Teva, he was a member of the Executive Committee of Bristol-Myers Squibb where he was globally responsible for overall strategy, alliances and business development. Prior to that, he was Global Head of Strategic Alliances at Novartis, where he established and managed strategic collaborations with multiple companies and research institutions around the world. Jeremy M. Levin’s special qualifications for serving on Lundbeck’s Board of Directors include a robust blend of clinical insight and experience, business development skills, corporate strategy and financial savvy. In addition he has substantial board experience. Jeremy M. Levin is member of the Board of Directors of BioCon in India, ZappRx and on the Board and Executive Committee of BIO, the Biotechnology Innovation Organization in the USA. It is proposed that the Board of Directors should receive the following remuneration for the current financial year: - Ordinary members will receive a basic remuneration of DKK 350,000 (increased from DKK 300,000) - The Chairman will receive three times the basic remuneration - The Deputy Chairman will receive two times the basic remuneration - Ordinary members of the Board Committees will receive DKK 200,000 in addition to the basic remuneration - The committee chairmen will receive DKK 300,000 in addition to the basic remuneration In accordance with the recommendation submitted to the Board of Directors by the Audit Committee, the Board of Directors proposes that Deloitte Statsautoriseret Revisions-partnerselskab should be re-elected. The Audit Committee is free from influence by a third party and is not subject to a contract with a third party restricting the choice of the general meeting to certain categories or lists of statutory auditors or audit firms, as regards the appointment of a particular statutory auditor or audit firm to carry out the statutory audit of the Company. It is proposed to authorise the Board of Directors until the next annual general meeting to allow the Company to acquire own shares of a total nominal value of up to 10% of the share capital in accordance with applicable law. The purchase price for the relevant shares may not deviate by more than 10% from the price quoted on Nasdaq Copenhagen A/S at the time of the acquisition. The Board of Directors proposes to authorise the Chairman of the general meeting to make such amendments and additions to the resolutions passed by the general meeting and the application for registration with the Danish Business Authority that may be required by the Danish Business Authority in connection with the registration of the adopted amendments. All proposals on the agenda may be adopted by a simple majority of votes. H. Lundbeck A/S welcomes all shareholders who have obtained an admission card for themselves and for any adviser accompanying them at the general meeting. Please note that admission cards must be obtained prior to the general meeting in order to attend. Access to the general meeting is via the reception on Otilliavej 9, DK-2500 Valby. There is limited parking space available on Ottiliavej and Postgården. In accordance with Article 10.1 of the Articles of Association, admission cards will be provided to shareholders entitled to vote at the general meeting. Anyone who is registered as a shareholder in the register of shareholders on the date of registration, 23 March 2017, or who has made a request to such effect, including evidence of title to shares, that has reached the Company on that date, is entitled to vote at the general meeting (see Article 10.4 of the Articles of Association). Admission cards for the general meeting can be obtained up to and including 24 March 2017 at the Company's website www.lundbeck.com, from Computershare A/S, Kongevejen 418, DK-2840 Holte, tel. +45 4546 0999, or by returning the request form to Computershare A/S. As a new initiative admission cards will be sent out electronically via email to the email address specified in the investor portal upon registration. The admission card must be presented at the general meeting either electronically on a smartphone/tablet or printed. Shareholders who have ordered admission cards without specifying their email address can pick up the admission card at the entrance of the general meeting upon presentation of valid ID. Voting cards will be handed out at the entrance of the general meeting. The Company's nominal share capital is DKK 988,186,125 divided into shares of DKK 5 nominal value. Each share of DKK 5 carries one vote as provided by Article 10.6 of the Articles of Association. The following information and documents will be made available on the Company's website, www.lundbeck.com, on 1 March 2017: 1) The notice convening the general meeting; 2) the total number of shares and voting rights at the date of the notice; 3) all documents to be submitted to the general meeting, including the audited annual report; 4) the agenda and the full text of all proposals to be submitted to the general meeting; and 5) postal and proxy voting forms. All shareholders may ask questions in writing about the agenda and the documents to be used for the general meeting. Questions may be sent by post or by email to email@example.com and will be answered prior to or at the general meeting. If you are prevented from attending the general meeting, the Board of Directors would be pleased to act as proxy to cast the votes attaching to your shares, in which case the proxy form, duly completed, dated and signed, must reach Computershare A/S, Kongevejen 418, DK-2840 Holte, by 24 March 2017. If you wish to appoint proxies other than to the Board of Directors, the form for appointing a third party as proxy can be used. The proxy forms are available on the Company's website, www.lundbeck.com. Proxies may also be appointed electronically on www.lundbeck.com on or before 24 March 2017 (please use custody account number and access code or the Danish NEMID). You may also vote by post by completing and signing the postal voting form and returning it to Computershare A/S, Kongevejen 418, DK-2840 Holte, so that it is received by 29 March 2017 at 12 noon. A postal voting form is available on the Company's website www.lundbeck.com, where votes may also be cast electronically. Also this year, Lundbeck offers simultaneous interpretation from Danish into English in the Auditorium. The general meeting will also be webcast live in Danish and English (can be replayed after the meeting). See the Company's website, www.lundbeck.com. If you have functional impairments which makes passage from the entrance to the Auditorium difficult you may request assistance from the staff upon arrival at the reception. H. Lundbeck A/S (LUN.CO, LUN DC, HLUYY) is a global pharmaceutical company specialized in psychiatric and neurological disorders. For more than 70 years, we have been at the forefront of research within neuroscience. Our key areas of focus are Alzheimer's disease, depression, Parkinson's disease and schizophrenia. Our approximately 5,000 employees in 55 countries are engaged in the entire value chain throughout research, development, manufacturing, marketing and sales. Our pipeline consists of several late-stage development programmes and our products are available in more than 100 countries. We have production facilities in Denmark, France and Italy. Lundbeck generated revenue of DKK 15.6 billion in 2016 (EUR 2.1 billion; USD 2.2 billion). For additional information, we encourage you to visit our corporate site www.lundbeck.com and connect with us on Twitter at @Lundbeck. The above information contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions, product approvals and financial performance. Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions. This may cause actual results to differ materially from expectations and it may cause any or all of our forward-looking statements here or in other publications to be wrong. Factors that may affect future results include interest rate and currency exchange rate fluctuations, delay or failure of development projects, production problems, unexpected contract breaches or terminations, government-mandated or market-driven price decreases for Lundbeck's products, introduction of competing products, Lundbeck's ability to successfully market both new and existing products, exposure to product liability and other lawsuits, changes in reimbursement rules and governmental laws and related interpretation thereof, and unexpected growth in costs and expenses. Certain assumptions made by Lundbeck are required by Danish Securities Law for full disclosure of material corporate information. Some assumptions, including assumptions relating to sales associated with product that is prescribed for unapproved uses, are made taking into account past performances of other similar drugs for similar disease states or past performance of the same drug in other regions where the product is currently marketed. It is important to note that although physicians may, as part of their freedom to practice medicine in the US, prescribe approved drugs for any use they deem appropriate, including unapproved uses, at Lundbeck, promotion of unapproved uses is strictly prohibited.
News Article | March 3, 2017
SEATTLE--(BUSINESS WIRE)--Impel NeuroPharma, a Seattle-based clinical-stage biotechnology company developing first-in-class intranasal drug treatments, announced today the appointment of Timothy S. Nelson as Independent Director of the Board of Directors. Mr. Nelson has over 20 years of experience with drug delivery, medical devices and drug device combinations. Most recently, Mr. Nelson served as MAP Pharmaceuticals’ President and CEO and as a member of its Board of Directors from April 2005 until March 2013. MAP was acquired by Allergan for $960 million. During that time, Mr. Nelson led the company through its initial public offering and developed LEVADEX, an inhaled dihydroergotamine for migraine. Prior to MAP, he served as Senior Vice President of Commercial and Business Development at DURECT Corporation and has held various senior management positions with Medtronic, including Business Director of the Neurological Division for Europe, the Middle East and Africa, and as Manager of Drug Delivery Ventures. Mr. Nelson has served on several boards, including Chairman of the Board of Civitas, a private biopharmaceutical company focused on treating undermet medical needs in neurological indications from December 2013 to October 2014. The company was acquired by Acorda Therapeutics for $525 million that year. He also served on the Board of Directors of Surmodics, a public medical technology company, from February 2014 to March 2015. Mr. Nelson holds a Master’s degree in Management with distinction from the Kellogg Graduate School of Management at Northwestern University and a Bachelors in Chemical Engineering from the University of Minnesota. “We are very excited to bring Tim onto Impel’s Board of Directors. Tim brings a deep knowledge of both medical devices and pharmaceutical products that will help Impel drive clinical development of our drug-device combination products,” said John Hoekman, Impel’s Founder & CEO. “Impel is developing nasally administered products to treat migraine, Parkinson’s, and Alzheimer’s disease. Tim’s experience and leadership will help Impel advance these therapies through clinical testing and into the hands of patients.” “Impel’s unique, cutting-edge technology has the potential to make a substantial step forward in more effective delivery of drugs which can mean better outcomes for millions of patients who are underserved by existing therapies,” Mr. Nelson said. “I am very pleased to be able to contribute to Impel’s mission and growth.” Impel NeuroPharma’s POD™ nasal drug delivery platform is designed to deliver drugs to the upper nasal cavity for improved biodistribution. By delivering therapeutics to the upper nasal cavity, the POD nasal delivery platform takes advantage of the vascular rich olfactory region for improved bioavailability and has the potential to target the brain via the olfactory and trigeminal nerves. Delivery of therapeutically meaningful levels of drugs may allow for development of more effective drugs and expand the range of treatment options available to patients. Impel NeuroPharma, Inc. is a Seattle-based company developing intranasal drug treatments for central nervous system (CNS) disorders. Impel NeuroPharma has developed a novel drug delivery platform, the POD™ technology, that administers drug to the deep nasal cavity to improve the biodistribution of many drugs. Impel NeuroPharma’s proprietary (POD) device technology enables entirely new categories of drugs, including biologics, to be administered using a cost-effective, disposable, non-invasive intranasal drug delivery device. To learn more about Impel NeuroPharma please visit our website: http://impelnp.com/. NOTICE: This document contains certain forward-looking statements, including without limitation statements regarding Impel NeuroPharma, Inc.’s plans for future research and development activities. You are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties inherent to Impel’s business which could significantly affect expected results, including without limitation progress of drug development, ability to raise capital to fund drug development, clinical testing and regulatory approval, developments in raw material and personnel costs, and legislative, fiscal, and other regulatory measures. All forward-looking statements are qualified in their entirety by this cautionary statement, and Impel’s undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.
News Article | February 20, 2017
Dublin, Feb. 20, 2017 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Global Coronary Stents Market (Bare Metal, Drug-Eluting, Bioresorable): Analysis By Segment, By Region, By Country (2016-2021)" report to their offering. Global Coronary Stents Market is forecasted to grow at a CAGR of 3.05% during 2016-2021F, on account of rising incidences of cardiovascular diseases globally leading to growing number of stent procedures. Rising development of bioresorbable stents combined with the growing awareness towards cardiovascular risks in developing countries has resulted in the growth of coronary stents market. Cardiovascular diseases are witnessing growth on account of the rise in the lifestyle related diseases including obesity, diabetes, hypertension etc. Among the types of coronary stents, market is expected to be driven by bioresorbable stents, mainly in the polylactic acid material. However, drug eluting stents will continue to generate major revenue while bare metal stents will further continue to decline. While developed regions will continue to dominate the market in terms of revenue, emerging nations are expected to respond to the market optimistically due to the developing healthcare infrastructure and rising focus on healthcare among the growing middle class population. Scope of the Report The report provides Segmentation by Stent Type: - Bare Metal stents - Drug-Eluting Stents - Bioresorbable Stents Key Topics Covered: 1. Research Methodology 2. Executive Summary 3. Strategic Recommendations 3.1. Bioresorbable Stents as the Future Market 3.2. Focus on Lowering of ASP in Coronary Stents 3.3. Opportunities in APAC Region 4. Global Coronary Stents Market: An Analysis 4.1. Product Overview 4.2. Global Coronary Stents Market 4.3. Global Coronary Stent Market, By Segments 4.4. Global Bare Metal Stents, By Value 4.5. Global Drug Eluting Stents, By Value 4.6. Global Bioresorbable Stents Market, By Segments 4.7. Global Coronary Stent Market, By Region 4.8. Coronary Stents: Pipeline Analysis 5. North America Coronary Stent Market: An Analysis 6. Europe Coronary Stent Market: An Analysis 7. APAC Coronary Stent Market: An Analysis 8. ROW Coronary Stent Market: An Analysis 9. Market Dynamics 9.1. Trends 9.2. Drivers 9.3. Challenges 10. Pricing Structure 11. Policy and Regulatory Landscape 12. M&A and Licensing Route to Coronary Stent Market 13. SWOT Analysis 14. Porter's Five Forces Model 15. Product Benchmarking 16. Company Profiles 16.1 Terumo Corporation 16.2 Boston Scientific 16.3 Stentys SA 16.4 MicroPort Scientific Corporation 16.5. Biotronik 16.6 Elixir Medical Corporation 16.7 Biosensors Inc. 16.8 Medtronic 16.9 Abbott Laboratories 16.10 Kyoto Medical Planning For more information about this report visit http://www.researchandmarkets.com/research/x2pdgt/global_coronary
News Article | February 28, 2017
DUBLIN, 28-Feb-2017 — /EuropaWire/ — Medtronic plc (NYSE:MDT) today announced that it has received CE (Conformité Européenne) Mark for a suite of quadripolar cardiac resynchronization therapy pacemakers (CRT-Ps) that also allow patients to receive MRI (magnetic resonance imaging) scans in either 1.5 or 3 Tesla (T) machines. This complete line of CRT-Ps, available in Europe in March, includes the Percepta(TM) Quad CRT-P MRI SureScan(TM), Serena(TM) Quad CRT-P MRI SureScan(TM) and Solara(TM) Quad CRT-P MRI SureScan(TM), and enables proactive heart failure management alongside industry-leading pacing technology and patient access to the most advanced diagnostic imaging procedures available. These devices are not yet approved for sale in the United States. “Quadripolar devices, such as these new pacemakers, allow more pacing programming options, which allows us to better optimize CRT delivery,” said Dr. Massimo Mantica of Istituto Clinica Sant’Ambrogio, Milano, Italy. “Advanced technology continues to give us smarter devices that enable more personalized treatment for patients.” The Percepta Quad CRT-P features the EffectivCRT(TM) Diagnostic, which automatically determines the effectiveness of each left ventricular pace, and the EffectivCRT(TM) during AF algorithm, which automatically adjusts pacing rates during atrial fibrillation (AF), without adversely affecting the average heart rate. It also includes VectorExpress(TM) 2.0, an automated in-office test that reduces lead programing to two minutes,1 and reveals clinically actionable information to help physicians select optimal pacing configurations for each patient. The Percepta Quad and Serena Quad CRT-Ps also feature the Medtronic-exclusive AdaptivCRT(TM) algorithm, which reduces a patient’s odds of a 30-day heart failure readmission by 59 percent,2 and has demonstrated a 46 percent reduction in AF risk compared to echo-optimized biventricular pacing.3 Both devices also feature Multiple Point Pacing, which can stimulate two sites on the left ventricle (lower chamber) simultaneously or sequentially. Additional features available in all three devices include: “With the addition of quadripolar CRT-P devices to our heart failure portfolio, we now offer a comprehensive line of CRT devices to further meet the needs of patients throughout Europe,” said David Steinhaus, M.D., vice president and general manager of the Heart Failure business, and medical director for the Cardiac Rhythm and Heart Failure division of Medtronic. “Our new quadripolar CRT-P devices include advanced, smart technologies that allow physicians to provide each patient with the appropriate therapy specific to his or her individual needs, all while offering access to advanced life-saving MRI technologies.” In collaboration with leading clinicians, researchers and scientists worldwide, Medtronic offers the broadest range of innovative medical technology for the interventional and surgical treatment of cardiovascular disease and cardiac arrhythmias. The company strives to offer products and services of the highest quality that deliver clinical and economic value to healthcare consumers and providers around the world. About Medtronic Medtronic plc (www.medtronic.com), headquartered in Dublin, Ireland, is among the world’s largest medical technology, services and solutions companies – alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 88,000 people worldwide, serving physicians, hospitals and patients in approximately 160 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together. Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic’s periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results. 1 Demmer, W. VectorExpress performance results. Medtronic data on file. January 2013. 2 Starling RC, Krum H, Bril S, et al. Impact of a Novel Adaptive Optimization Algorithm on 30-Day Readmissions: Evidence From the Adaptive CRT Trial. JACC Heart Fail. July 2015;3(7):565-572. 3 Martin D, et al. Clinical outcomes with adaptive cardiac resynchronization therapy: Long-term outcomes of the Adaptive CRT Trial. HFSA Annual Scientific Meeting. September 23, 2013. 4 Biffi et al. Effort of bipolar electrode spacing on phrenic nerve stimulation and left ventricular pacing thresholds: An acute canine study. Circulation Arrhythmia and Electrophysiology. 2012.
News Article | March 1, 2017
Changing mindset in manufacturing Quality Management provides an opportunity for quality professionals to shift to a strategic, proactive approach that benefits their companies and their careers FAIRFAX, VA--(Marketwired - Mar 1, 2017) - InfinityQS® International, Inc. (InfinityQS), the global authority on data-driven enterprise quality, advises manufacturers to reconsider their approach to Quality Management. By moving out of "firefighting" mode and into a proactive, data-driven mindset, quality professionals can solve problems more quickly -- or even prevent them in the first place. As a result, quality teams can focus instead on finding opportunities to improve operations and product quality. Most quality professionals operate in fire drill mode in a landscape of problem alarms and reactive decision-making. Because problems are typically identified after a process or machine fails or quality checks show that products fall outside of specifications, quality teams are left scrambling to minimize damage, including rework, recall, and lost time and productivity. Michael Lyle, President and CEO, InfinityQS, said, "Most Quality Management solutions operate under a short-sighted reactive status quo. The system might alert you to problems that have already occurred, but they don't have the capacity to help you predict and prevent problems -- or locate potential areas for improvement across the manufacturing enterprise. Doing so can provide manufacturers a competitive advantage." InfinityQS suggests that manufacturers turn instead to a Quality Management approach that unifies quality data from across the entire enterprise and leverages advanced analytics to enable insight into operational variances over time. This type of solution enables quality teams to notice small changes in processes or machine performance that indicate the early stages of an issue. By predicting problems in this way, manufacturers can catch issues earlier. Even more important is the fact that this level of insight can also be used to proactively identify opportunities for improvement that can significantly increase yield and efficiency across the enterprise. This converts quality professionals from reactive firefighters into quality and process strategists identifying competitive improvement opportunities. To learn more about how data-driven, operational insight can benefit quality teams and provide a competitive advantage for manufacturers, download InfinityQS's new white paper, "Operational Insight: Information That Drives Excellence." About InfinityQS International, Inc. InfinityQS International, Inc. is the global authority on data-driven enterprise quality. The company's Manufacturing Intelligence solutions deliver unparalleled visibility across the enterprise, from the shop floor to the boardroom, enabling manufacturers to Re-imagine Quality and transform it from a problem into a competitive advantage. Powered by centralized analytics, InfinityQS's solutions provide operational insight to enable global manufacturers to improve product quality; decrease costs and risk; maintain or improve compliance; and make strategic, data-driven business decisions. Headquartered near Washington, D.C., with offices in Seattle, London, and Beijing, InfinityQS was founded in 1989 and now services more than 45,000 active licenses with more than 2,500 of the world's leading manufacturers, including Ball Corporation, Boston Scientific, Graham Packaging, and Medtronic. For more information, visit www.infinityqs.com.
News Article | February 22, 2017
The Global Automated External Defibrillator Market 2016 Industry Research Report is a professional and in-depth study on the current state of the Automated External Defibrillator industry. Firstly, the report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Automated External Defibrillator market analysis is provided for the international market including development history, competitive landscape analysis, and major regions’ development status. Secondly, development policies and plans are discussed as well as manufacturing processes and cost structures. This report also states importexport, supply and consumption figures as well as cost, price, revenue and gross margin by regions (North America, EU, China and Japan), and other regions can be added. Then, the report focuses on global major leading industry players with information such as company profiles, product picture and specification, capacity, production, price, cost, revenue and contact information. Upstream Main Components, equipment and downstream consumers analysis is also carried out. What’s more, the Automated External Defibrillator industry development trends and marketing channels are analyzed. Finally, the feasibility of new investment projects is assessed, and overall research conclusions are offered. In a word, the report provides major statistics on the state of the industry and is a valuable source Analytics and data presented in each report pertain to several parameters such as – Global and Regional Market Sizes, Market Shares, Market Trends Product (Global and Regional) Market Sizes, Market Shares, Market Trends Technology Trends Corporate Intelligence Key Companies By Sales, Brands, Products Other Strategic Business Affecting Data 1 Industry Overview of Automated External Defibrillator 1 1.1 Definition and Specifications of Automated External Defibrillator 1 1.1.1 Definition of Automated External Defibrillator 1 1.1.2 Specifications of Automated External Defibrillator 1 1.2 Classification of Automated External Defibrillator 3 1.3 Applications of Automated External Defibrillator 4 1.3.1 Hospitals 5 1.3.2 Public access 6 1.3.3 Home 6 1.3.4 Training 7 1.4 Industry Chain Structure of Automated External Defibrillator 7 1.5 Industry Overview and Major Regions Status of Automated External Defibrillator 8 1.5.1 Industry Overview of Automated External Defibrillator 8 1.5.2 Global Major Regions Status of Automated External Defibrillator 9 1.6 Industry Policy Analysis of Automated External Defibrillator 9 1.7 Industry News Analysis of Automated External Defibrillator 10 8 Major Manufacturers Analysis of Automated External Defibrillator 71 8.1 Philips 71 8.1.1 Company Profile 71 8.1.2 Product Picture and Specifications 72 8.1.3 Production, Price, Cost, Gross and Revenue 73 8.1.4 Contact Information 75 8.2 Zoll 75 8.2.1 Company Profile 75 8.2.2 Product Picture and Specifications 76 8.2.3 Production, Price, Cost, Gross and Revenue 77 8.2.4 Contact Information 78 8.3 Medtronic 78 8.3.1 Company Profile 78 8.3.2 Product Picture and Specifications 79 8.3.3 Production, Price, Cost, Gross and Revenue 80 8.3.4 Contact Information 82 8.4 Laerdal Medical 82 8.4.1 Company Profile 82 8.4.2 Product Picture and Specifications 83 8.4.3 Production, Price, Cost, Gross and Revenue 84 8.4.4 Contact Information 86 8.5 Cardiac Science 86 8.5.1 Company Profile 86 8.5.2 Product Picture and Specifications 87 8.5.3 Production, Price, Cost, Gross and Revenue 88 8.5.4 Contact Information 90 8.6 Nihon Kohden 90 8.6.1 Company Profile 90 8.6.2 Product Picture and Specifications 91 8.6.3 Production, Price, Cost, Gross and Revenue 91 8.6.4 Contact Information 93 8.7 Schiller 93 8.7.1 Company Profile 93 8.7.2 Product Picture and Specifications 94 8.7.3 Production, Price, Cost, Gross and Revenue 95 8.7.4 Contact Information 96 8.8 HeartSine Technologies 96 8.8.1 Company Profile 96 8.8.2 Product Picture and Specifications 97 8.8.3 Production, Price, Cost, Gross and Revenue 100 8.8.4 Contact Information 102 8.9 A.M.I. Italia 102 8.9.1 Company Profile 102 8.9.2 Product Picture and Specifications 102 8.9.3 Production, Price, Cost, Gross and Revenue 103 8.9.4 Contact Information 105 8.10 Defibtech 105 8.10.1 Company Profile 105 8.10.2 Product Picture and Specifications 106 8.10.3 Production, Price, Cost, Gross and Revenue 106 8.10.4 Contact Information 108 8.11 Metrax GmbH 108 8.11.1 Company Profile 108 8.11.2 Product Picture and Specifications 109 8.11.3 Production, Price, Cost, Gross and Revenue 110 8.11.4 Contact Information 111 8.12 Mediana 111 8.12.1 Company Profile 111 8.12.2 Product Picture and Specifications 112 8.12.3 Production, Price, Cost, Gross and Revenue 113 8.12.4 Contact Information 115 8.13 Instramed 115 8.13.1 Company Profile 115 8.13.2 Product Picture and Specifications 116 8.13.3 Production, Price, Cost, Gross and Revenue 116 8.13.4 Contact Information 118 8.14 METsis Medikal 118 8.14.1 Company Profile 118 8.14.2 Product Picture and Specifications 119 8.14.3 Production, Price, Cost, Gross and Revenue 119 8.14.4 Contact Information 121 8.15 Mindray 121 8.15.1 Company Profile 121 8.15.2 Product Picture and Specifications 122 8.15.3 Production, Price, Cost, Gross and Revenue 123 8.15.4 Contact Information 124 8.16 Beijing M&B Electronic 124 8.16.1 Company Profile 124 8.16.2 Product Picture and Specifications 125 8.16.3 Production, Price, Cost, Gross and Revenue 126 8.16.4 Contact Information 128 8.17 Shenzhen XFT 128 8.17.1 Company Profile 128 8.17.2 Product Picture and Specifications 130 8.17.3 Production, Price, Cost, Gross and Revenue 130 8.17.4 Contact Information 132 For more information, please visit https://www.wiseguyreports.com/sample-request/982340-global-automated-external-defibrillator-market-2017-industry-research-report